We are your trusted health partner. Local doorstep deliveries is within the hour .We are Licensed and Regulated by the Pharmacist's Council of Nigeria(PCN).Prices displayed here may differ due to inflation.
Prostap 3 DCS 11.25mg is a prescription-only, ultra-high-potency gonadotropin-releasing hormone (GnRH) agonist. It contains Leuprorelin Acetate (11.25mg) formulated as an advanced, sustained-release micro-suspension.
The number 3 indicates that this is a long-acting formulation engineered to provide continuous medical suppression for a full 3 months. The abbreviation DCS stands for Dual Chamber Syringe, an integrated system that isolates the sterile, dry hormone microcapsule powder in the front chamber and 1mL of specialized liquid solvent in the rear chamber until the exact moment of administration. It is injected exactly once every 12 weeks (84 days) to systematically shut down the body's natural production of sex hormones (testosterone in men and estrogen in women).
Prostap 3 DCS alters the body’s hormonal architecture through a deliberate, two-phase process:
The Initial Surge (The 1st Week): When first injected, the leuprorelin molecules over-stimulate the pituitary gland, causing a brief surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This triggers a temporary, transient rise in circulating testosterone or estrogen levels.
The Down-Regulation Blockade (Continuous Phase): After a week of continuous contact, the pituitary gland's receptors switch off entirely. This shuts down LH and FSH secretion, dropping sex hormones to near-zero (castrate baseline in men and menopausal baseline in women).
12-Week Extended Release: The 11.25mg microcapsules dissolve exceptionally slowly under the skin or inside the muscle, providing a stable, unyielding chemical barrier for a full 3 months, reducing the frequency of clinic visits.
Advanced Prostate Cancer: Long-term management of locally advanced or metastatic prostate cancer, serving as a highly effective medical alternative to surgical castration. It can also be used as a companion treatment alongside radical prostatectomy or local radiotherapy.
Endometriosis: Treating tissue resembling the womb lining that grows outside the uterus, reducing chronic pelvic inflammation and severe menstrual pain over a extended therapeutic window.
Uterine Fibroids Preoperative Management: Shrinking non-cancerous muscle tumors in the womb over 3 to 4 months to reduce their overall mass and minimize bleeding complications before a scheduled surgery.
During the first 1 to 2 weeks of starting Prostap 3 DCS, the initial spike in testosterone can cause a brief worsening of prostate cancer symptoms. This can manifest as increased bone pain, difficulty urinating, or spinal cord pressure. To prevent this, oncologists standardly prescribe an oral anti-androgen pill (such as Casodex/Bicalutamide) to be taken daily starting a few days before your first injection to act as a protective barrier.
Because sex hormones keep bones strong, suppressing them causes temporary bone thinning (osteoporosis). For benign gynecological conditions like endometriosis or fibroids, Prostap 3 DCS therapy is strictly limited to a maximum of 6 months (two 3-month injections). Specialists often co-administer a low-dose "add-back" Hormone Replacement Therapy (HRT) to protect your skeletal matrix and ease menopausal side effects.
Unexplained or undiagnosed abnormal vaginal bleeding.
Pregnancy and Breastfeeding: Prostap 3 DCS is strictly contraindicated. Pregnancy must be completely ruled out before starting treatment, and therapy in women must begin during the first 5 days of their menstrual cycle. Non-hormonal barrier birth control (like condoms) must be used throughout the course.
Strictly Professional Use: Prostap 3 DCS can be injected either subcutaneously (under the skin) or deep intramuscularly (into the muscle). It must only be prepared and administered by a qualified healthcare professional.
Vary the Injection Site: The injection location must be rotated periodically between appointments to prevent localized skin tissue thickening.
1.Screw in the plunger and verify the needle:Assembly.
The healthcare professional removes the syringe from the sterile pack and screws the plunger rod firmly into the bottom stopper until it begins to rotate.
2.Push the plunger slowly to release the liquid:Reconstitution.
Holding the syringe completely upright, push the plunger forward slowly. This moves the internal stoppers and forces the liquid solvent from the rear chamber into the front chamber containing the white powder. Stop pushing when the middle stopper hits the blue line.
3.Tap the syringe gently against your palm:Mixing.
Gently tap the syringe against the palm of your hand. Do not shake hard, as this creates excessive air bubbles. Keep tapping until the powder fully dissolves, forming a smooth, uniform, milky suspension with no lumps.
4.Expel air bubbles and inject immediately:Prime and Inject.
Remove the needle cap, gently push the plunger to expel excess air bubbles, and inject the entire contents immediately. The micro-suspension settles out exceptionally fast; if delayed, the needle will clog.
5.Activate the safety shield with a click:Safety Guard.
Upon withdrawing the needle from the patient's skin, immediately press the upward arrow safety device until a distinct "CLICK" is heard or felt, fully covering the needle to prevent stick injuries.
As your system adjusts to the near-total suppression of reproductive hormones, you will experience typical hormonal updates:
In Men: Frequent hot flushes, sudden sweating, temporary erectile dysfunction, a reduction in testicle size, and temporary bone or joint pain during the first 2 weeks.
In Women: Hot flushes, night sweats, pronounced vaginal dryness, mood shifts, anxiety, temporary headaches, and unexpected breakthrough spotting or vaginal bleeding during the first month before periods fully cease.
Localized minor bruising, redness, or a brief dull ache where the needle entered.
What happens if I delay my 12-weekly Prostap 3 DCS injection by a week or two?
To maintain a steady, unyielding block against hormone production, you must receive your injection precisely every 12 weeks. If you miss your scheduled date, your hormone levels can begin to rebound rapidly, which can cause your symptoms to flare back up or lower the effectiveness of your therapy. Contact your clinic immediately to get your routine back on track.
Can Prostap 3 DCS affect my blood sugar or heart health?
Yes. Long-term hormone deprivation therapy can cause metabolic shifts, including a reduction in sugar tolerance (potentially worsening diabetes) and minor increases in blood pressure or cholesterol levels. If you have diabetes, you should increase the frequency of your blood glucose monitoring at home and share your logs with your physician.
How should this pre-filled kit be stored before my clinic appointment?
Keep your unopened Prostap 3 DCS box stored inside a cool, dry room strictly below 25°C and away from direct sunlight. Do not store it in a refrigerator or freezer. Freezing can permanently damage the sustained-release microcapsules and render the solution ineffective.
Advanced endocrine and oncological micro-suspensions require absolute supply chain integrity, strictly regulated storage parameters ($<25^{\circ}\text{C}$), and professional batch tracking to guarantee therapeutic delivery and protect patient outcomes. You can submit your specialist’s medical prescription and purchase genuine, factory-authenticated Prostap 3 DCS 11.25mg Dual Chamber Syringes (manufactured by Takeda) online through Sanlive Pharmacy & Stores for secure payment and fast, reliable same-day delivery directly to your home, office, or specialist clinic within Lagos, Abuja, and Port Harcourt. We also provide nationwide delivery through our trusted specialty clinical logistics channels to deliver your essential oncology or reproductive care safely anywhere in Nigeria.
Important Notice: This information is for educational support and clinical procurement purposes only. Prostap 3 DCS 11.25mg is a high-potency, prescription-only specialized injection. Your entire treatment protocol must be initiated, monitored, and adjusted under the direct care of a registered oncologist, gynecologist, or qualified medical specialist. If you experience sudden chest pain, rapid heart palpitations, signs of a deep vein thrombosis or pulmonary embolism (severe calf pain or sudden shortness of breath), or a severe blistering skin rash, seek immediate emergency medical care at a hospital.
No reviews yet — be the first!
Log in to write a review.
.jpg)
